Kintor Pharma begins Phase II trial of KX-826 for androgenetic alopecia treatment
pharmafile | November 12, 2021 | News story | Medical Communications |
Kintor Pharma, a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced that the company has dosed the first patient in its Phase II clinical trial of pyrilutamide (KX-826) in China, for the treatment of female patients with androgenetic apolecia (AGA).
The Phase II trial is a randomised, double-blind, placebo-controlled, multi-regional study to test the efficacy and safety profile of KX-826. The primary endpoint for the trial is the change from baseline in non-vellus target area hair counts (TAHC) at week 24.
Androgenetic Alopecia is a common form of hair loss in both men and women. The progression of the condition tends to be very slow, and can span several years to decades. It is mediated by the presence of the androgen dihydrotestosterone (DHT), which comes from testosterone. This attacks your hair follicles, causing your hair to fall out, and prevents growth.
KX-826 is an androgen receptor (AR) antagonist, and a potential first-in-class topical drug for the treatment of AGA and acne vulgaris.
Dr. Youzhi Tong, founder, Chairman and CEO of Kintor Pharma, commented, “The population of those who suffer from hair loss has a large number and tends to be younger. By the end of 2020, the number of hair loss in China had exceeded 252 million, among which about 87 million were women. AGA accounts for approximately 90% of patients with hair loss, but there are few therapeutic drugs. So, a safer and more effective drug is in urgent need to address the concerns for the people suffering from hair loss.
“As a topical AR antagonist with an identified target, KX-826 has showed good efficacy and safety profile in the phase II clinical trial in China for the treatment of AGA male patients. We look forward to further expanding the clinical potential of KX-826 and benefiting more people suffering from hair loss.”